RecruitingNot applicableNCT06886425
Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies
Studying Myelodysplastic syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Assistance Publique Hopitaux De Marseille
- Intervention
- genetic study(other)
- Enrollment
- 70 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2028
Study locations (1)
- Hôpital de la Conception, Marseille, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06886425 on ClinicalTrials.govOther trials for Myelodysplastic syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06630221Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 MutationsAbhay Singh, MD MPH
- RECRUITINGPHASE1, PHASE2NCT06548230A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)M.D. Anderson Cancer Center
- RECRUITINGPHASE2NCT06802315Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)University of Illinois at Chicago
- ACTIVE NOT RECRUITINGPHASE2NCT07052006A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and AnemiaHalia Therapeutics, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT05201066Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.Novartis Pharmaceuticals
- ACTIVE NOT RECRUITINGPHASE3NCT04401748Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic SyndromeAbbVie
- ACTIVE NOT RECRUITINGPHASE2NCT02912208Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic SyndromesAssociazione Qol-one